Fans of the TIGIT mechanism finally have something to cheer about after iTeos Therapeutics Inc.'s belrestotug impressed in a mid-stage trial lung cancer trial when combined with GSK plc's PD-1 inhibitor Jemperli.
ESMO 24: GSK and iTeos Chalk Up Much-Needed Win For TIGIT
While oncology heavyweights Roche and Merck & Co have failed to make much headway with their in-house TIGIT offerings, hopes are high for iTeos's belrestotug in combination with GSK's checkpoint inhibitor, Jemperli, which has demonstrated promising response rates for non-small cell lung cancer in the Phase II GALAXIES Lung-201 study.
More from Immuno-oncology
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
• By
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.
• By
The MATTERHORN study could set Imfinzi up for another new perioperative use, even though the gastric cancer trial has yet to demonstrate an overall survival benefit.
More from Anticancer
• By
Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.
• By
The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.